Compare BLFY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLFY | IKT |
|---|---|---|
| Founded | 1939 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.3M | 201.3M |
| IPO Year | N/A | 2020 |
| Metric | BLFY | IKT |
|---|---|---|
| Price | $13.07 | $1.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $10.00 | $6.00 |
| AVG Volume (30 Days) | 483.7K | ★ 522.9K |
| Earning Date | 01-21-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,731,000.00 | N/A |
| Revenue This Year | $19.85 | N/A |
| Revenue Next Year | $20.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.52 | N/A |
| 52 Week Low | $7.61 | $1.33 |
| 52 Week High | $13.55 | $3.32 |
| Indicator | BLFY | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 60.49 | 47.33 |
| Support Level | $12.77 | $1.63 |
| Resistance Level | $13.55 | $1.88 |
| Average True Range (ATR) | 0.36 | 0.10 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 69.65 | 24.15 |
Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.